Sign inJoin waitlistJoin the waitlist

ML

Monica Longo

Program Officer for Several Clinical Trials · NICHD

Credentials: · · · · · · ·

History

MedStar Health
2022–Present

Maternal-Fetal Medicine
University of Texas Health Science Center at Houston
2016–2018
Obstetrics and Gynecology
University of Texas Medical Branch Hospitals
2011–2013
University of Modena
1996–1997
University of Texas Medical Branch at Galveston
UNIV DE MODENA, MODENA
1992–1996

Research

Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications
JAMA · 2022 · 220 citations
The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice
American Journal of Obstetrics and Gynecology · 2007 · 173 citations
Prediction of vaginal birth after cesarean delivery in term gestations: a calculator without race and ethnicity
American Journal of Obstetrics and Gynecology · 2021 · 152 citations

George Saade
73 papers
Maged Costantine
35 papers · 11 as a fellow
DR
Dwight Rouse
32 papers
GH
Gary Hankins
30 papers
William Grobman
30 papers
Hyagriv Simhan
29 papers
Alan Tita
26 papers
Jennifer Bailit
22 papers
Cynthia Gyamfi-Bannerman
21 papers
Torri Metz
19 papers
John Thorp
18 papers
George Macones
15 papers

Grants

In Utero Programming of Adult Vascular Function
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.1M · University of Texas Med Br Galveston
2005–2010

Clinical trials

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Study director · Recruiting · Phase 3
The George Washington University Biostatistics Center
2024–2027
Opioid Prescription After Cesarean Trial
Study director · Completed · Phase 3
The George Washington University Biostatistics Center
2020–2022
Maternal Morbidity and Mortality During the COVID-19 Pandemic
Study director · Completed
The George Washington University Biostatistics Center
2020–2021
Pravastatin to Prevent Preeclampsia
Study director · Terminated · Phase 3
The George Washington University Biostatistics Center
2019–2024